26 avril 2012: Prof. Douglas Hanahan

Thursday, April 26th 2012, 12h30

Prof. Douglas Hanahan
Director Swiss Institute for Experimental Cancer Research
(Institut Suisse de Recheche Expérimentales sur le Cancer)
Professor of Molecular Oncology, School of Life Sciences, EPFL


"Translational Therapeutic Oncology: Linking Pre-Clinical and Clinical Cancer Trials"


Douglas Hanahan, is a world-renowned researcher in molecular oncology director of ISREC, the Swiss Institute for Experimental Cancer Research at EPFL,Lausanne.
Born in 1951, Douglas Hanahan is an American national who holds a degree in physics from the Massachussetts Institute of Technology and a PhD in biophysics from Harvard University, the latter involving research in molecular genetics and biotechnology both at Harvard and the Cold Spring Harbor Laboratory in.
He worked as a senior scientist at CSHL from 1983 to 1988, where he developed innovative models for studying human cancer, work he continued upon joining the University of California at San Francisco, where he is currently a full professor of biochemistry and biophysics, a member of the comprehensive cancer center, and a prestigious American Cancer Society Research Professor. His current research is investigating the role of angiogenesis and the microenvironment in tumor development and progression, and the prospects for applying knowledge of cancer mechanisms to the development of more “targeted” therapies.
He is being recognized for his contributions to cancer science and biotechnology, exemplified by his recent election to the Institute of Medicine of the U.S. National Academy of Sciences. He has published about 380 papers in top ranked journals